OmniComm Systems Announces First Australia Client FORT

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
OmniComm Systems Announces First Australia Client

FORT LAUDERDALE, Fla., Oct. 06, 2016 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OmniComm) (OTCQX:OMCM), a global leading provider of clinical data management technology, today announced that Scientia Clinical Research, Australia’s newest and most advanced early phase clinical trial facility at the University of New South Wales in Sydney, Australia has selected OmniComm’s TrialOne clinic automation and eSource application.  Scientia Clinical Research is the first purpose built early phase clinical trials center in Sydney, Australia.  In addition to first-in-human and first-in-patient studies, the facility will also support later phase trials across a broad range of disciplines.  TrialOne will standardize processes, improve business intelligence, ensure compliance, and achieve overall business transformation within its early phase research.

“Scientia Clinical Research believes TrialOne will deliver a competitive advantage in the early phase clinical trial space in Australia,” says Lisa Nelson, CEO at Scientia Clinical Research.

TrialOne is a browser-based bedside data collection technology specifically designed to automate the workflows and processes within early phase research clinics.  TrialOne enables the automation of clinic data collection; standardizes recruiting; facilitates the collection of study data and sample tracking; reduces discrepancies inherent in paper-based applications; and ensures compliance.

TrialOne is the market leading eSource system for early phase research clinics addressing the following needs of this organization:

  • Manage and optimize patient screening and recruitment
  • Provide secure and fully validated eSource
  • Implement protocol compliant workflows and data capture from subject bedside
  • Deliver automated data capture from medical monitoring equipment and devices
  • Streamline staff training and support records
  • Provide integration with laboratory information management systems (LIMS) for lab orders and lab results processing

“We are extremely proud that Scientia Clinical Research selected TrialOne early phase clinic automation solution for their state of the art, purpose built clinical trial center.  Scientia is OmniComm’s first customer in Australia and New Zealand.  This represents a decisive step for OmniComm in its penetration of the early phase and clinical trials market in Australia.  Having Scientia as a high profile, top level customer will aid OmniComm in its regional expansion, not only with TrialOne but with all our products,” says Wolf Ondracek, managing director and SVP for the APAC region at OmniComm.  “We are extremely pleased to be partnering and working with such a world-class organization as Scientia Clinical Research.”

About OmniComm Systems, Inc. OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments.  Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,800 clinical trials. For more information, visit www.omnicomm.com .

Trademarks OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.

Dennis Constantinou OmniComm Systems, Inc. +1.954.473.1254 dconstantinou@omnicomm.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 35

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 28

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 15

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 44

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 24

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 29

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 33

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading

Top 5 Most Recently Viewed Articles

CareDx and Dovetail Genomics Forge New Path in Transplant Solutions

Updated Category News Views 79

Partnership to Enhance HLA Typing Technology CareDx, Inc. (NASDAQ: CDNA), renowned for its pioneering precision medicine approach for transplant patients, has recently joined forces with Dovetail Genomics, a recognized leader in genomic solutions. This notable collaboration is set to introduce an Early Access Program designed for HLA laboratories, leveraging a unique...

Continue Reading
Pet Valu Holdings Secures C$150 Million Through Secondary Offering

Updated Category News Views 285

Pet Valu Holdings Hits Milestone with Recent Secondary Offering MARKHAM, Ontario — Pet Valu Holdings Ltd. (“Pet Valu” or the “Company”) (TSX: PET), a prominent name in Canadian specialty retailing, has unveiled the successful completion of its secondary bought deal offering. This initiative has generated an impressive C$150 million through the sale of 5,200,000...

Continue Reading
SMCP Settles Legal Proceedings Over 15.9% Stake Dispute

Updated Category News Views 116

Overview of SMCP's Recent Legal Developments In a significant update, SMCP has received confirmation regarding the legal proceedings related to a notable 15.9% stake in its share capital. The London Court of Appeal has denied requests from Dynamic Treasure Group (DTG) to appeal the High Court's decision, which ruled the sale of shares to DTG as invalid. This ruling...

Continue Reading
Grit Real Estate Announces Important AGM Details for Shareholders

Updated Category News Views 91

Grit Real Estate Income Group's Upcoming AGM Grit Real Estate Income Group Limited, a pan-African leader in real estate, has made a significant announcement regarding its forthcoming Annual General Meeting (AGM). This event is set to take place on a Friday, specifically at 14h30 Mauritian time. Although the exact location is specified, the company invites all eligible...

Continue Reading
Petaluma Enriches Pet Nutrition with Dr. Sarah Dodd

Updated Category News Views 271

Petaluma Welcomes Dr. Sarah Dodd as Advisor and Formulator Petaluma, a forward-thinking sustainable pet nutrition company, is excited to announce the addition of Dr. Sarah Dodd as an Advisor and Formulator. Dr. Dodd is a renowned figure in the field of plant-based pet nutrition, bringing with her a wealth of experience to transform pet food for a sustainable and humane...

Continue Reading